And adding to my post, after the trofinetide approval, in my opinion, Neuren must focus immediately on proving NNZ2591 in other rare syndromes in mouse models, in anticipation of successful 3 or 4 P2 trials results which may come around the middle of 2023. Proving NNZ2591 in additional rare syndromes in mouse models would be other significant point when it comes to negotiating US rights for NNZ2591 after P2 trials.
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-28
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.39 |
Change
-0.470(2.37%) |
Mkt cap ! $2.478B | |||
| Open | High | Low | Value | Volume |
| $19.70 | $19.77 | $19.28 | $10.38M | 534.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2680 | $19.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.41 | 362 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |